Abstract
Background An accurate measure of the impact of COVID-19 is the infection fatality ratio, or the proportion of deaths among those infected, which does not depend on variable testing rates between nations. The risk of mortality from COVID-19 depends strongly on age and current estimates of the infection fatality ratio do not account for differences in national age profiles. Comparisons of cumulative death trajectories allow the effect and timing of public health interventions to be assessed.
Our purpose is to (1) determine whether countries are clustered according to infection fatality ratios and (2) compare interventions to slow the spread of the disease by clustering death trajectories.
Methods National age standardised infection fatality ratios were derived from age stratified estimates from China and population estimates from the World Health Organisation. The IFRs were clustered into groups using Gaussian mixture models. Trajectory analysis clustered cumulative death rates in two time windows, 50 and 100 days after the first reported death.
Findings Infection fatality ratios from 201 nations were clustered into three groups: young, medium and older, with corresponding means (SD) of 0.20% (0.03%), 0.38% (0.11%) and 0.93% (0.21%).
At 50 and 100 days after the first reported death, there were two clusters of cumulative death trajectories from 113 nations with at least 25 deaths reported at 100 days. The first group had slowly increasing or stable cumulative death rates, while the second group had accelerating rates at the end of the time window. Fifty-two nations changed group membership between the time windows.
Conclusion A cluster of younger nations have a lower estimated infection fatality ratio than older nations. The effect and timing of public health interventions in preventing the spread of the disease can be tracked by clustering death rate trajectories into stable or accelerating and comparing changes over time.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
TLK and GH were funded by the Australian Government's Medical Research Future Fund (https://www.health.gov.au/initiatives-and-programs/medical-research-futurefund) as part of the Rapid Applied Research Translation program (MRF9100005). It is part of the work being undertaken by Health Translation SA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes